1 |
Huang SF, Liu HP, Li LH (2004). High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancer related to gefitinib responsiveness in Taiwan. Clin Cancer Res, 10, 8195-203.
DOI
ScienceOn
|
2 |
Inal A, Kaplan MA, Kucukoner M, et al (2012). Prognostic factors for second-line treatment of advanced non-small-cell lung cancer: retrospective analysis at a single institution. Asian Pac J Cancer Prev, 13, 1281-4.
DOI
ScienceOn
|
3 |
Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
DOI
|
4 |
Lynch TJ, Bell DW, Sordella R (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39.
DOI
ScienceOn
|
5 |
Marchetti A, Martella C, Felicioni L (2005). EGFR mutations in non-small cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol, 23, 857-65.
DOI
ScienceOn
|
6 |
MILLER VA, O'CONNOR P, SOH C (2009). A randomized, double-blind, placeb controlled, phase IIIb trial (atlas) comparing bevacizumab(B) therapy with or without erlotinib(E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic nonsmall cell lung. J Clin Oncol, 27, abstrLBA8002.
|
7 |
Mu XL, Li LY, Zhang XT (2005). Gefitinib-sensitive mutations of the epidermal growth factor receptor thyosine domain in Chinese patients with non-small cell lung cancer. Clin Cancer Res, 11, 4289-94.
DOI
ScienceOn
|
8 |
Paez JG, Janner PA, Lee JC(2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500.
DOI
ScienceOn
|
9 |
Pao W, Miller V, Zakowski M (2004). EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA, 101, 13306-11.
DOI
ScienceOn
|
10 |
Qin BM, Chen X, Zhu JD (2005). Identification of EGFR kinase domain mutaitions among lung cancer patients in China:implication for targeted cancer therapy. Cell Res, 15, 212-7.
DOI
ScienceOn
|
11 |
Shigematsu H, Lin L, Takahashi T (2005). Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst, 97, 339-46.
DOI
ScienceOn
|
12 |
Tokumo M, Toyooka S, Kiura K (2005). The relationship between epidermal gorwth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res, 11, 1167-73.
|
13 |
Xiao H, Ding J, Gao S, Yang S, Huang Y (2011). Never smokers with lung cancer: analysis of genetic variants. Asian Pac J Cancer Prev, 12, 2807-9.
|
14 |
Zhou C, Wu YL, Chen G, et al (2011). Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, openlabel, randomised, phase 3 study. Lancet Oncol, 12, 735-42.
DOI
ScienceOn
|